Parkinson's disease clinical trials

Explore recruiting parkinson's disease clinical trials.

Recruiting parkinson's disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Parkinson's disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Multicenter, randomized, double-blind, and placebo-controlled clinical trial to assess the efficacy and safety of donepezil versus placebo in mild cognitive impairment associated with Parkinson's disease.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson’s Disease (NEULARK)

Spain, Poland, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Independent, multicenter, phase IV, randomized, double-blind, parallel-group clinical trial in people with Parkinson's Disease under stable dopaminergic treatment with persistent fatigue symptoms, randomized 1:1 to adjunctive treatment with safinamide (100 mg/day) or rasagiline (1 mg/day) for 24 weeks.

Spain

Therapeutic use (Phase IV) EU CTIS Study details

Management of peripheral levodopa resistance in Parkinson’s disease

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Pathophysiology of pain in Parkinson's disease: exploration of the serotonin system in positron emission tomography (PET [18F]-MPPF) - PD PAIN

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A study to compare the absorption of two tablet strengths with the absorption of a solution.

Netherlands

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Parkinson's disease trials by city

Parkinson's disease in Toronto Parkinson's disease in Vancouver Parkinson's disease in Montreal Parkinson's disease in Calgary Parkinson's disease in Edmonton Parkinson's disease in Ottawa Parkinson's disease in Winnipeg Parkinson's disease in Quebec City Parkinson's disease in Hamilton Parkinson's disease in Kitchener Parkinson's disease in London Parkinson's disease in Halifax Parkinson's disease in New York Parkinson's disease in Los Angeles Parkinson's disease in Chicago Parkinson's disease in Houston

Other conditions

Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease IgA nephropathy Polycystic kidney disease Migraine Alzheimer's disease Multiple sclerosis Epilepsy ALS Huntington's disease Peripheral neuropathy Restless legs syndrome Essential tremor Dementia Depression Anxiety Bipolar disorder Schizophrenia